NexImmune, Inc.: Nasdaq/NYSE listing notice — NexImmune receives Nasdaq delisting notice for being a 'public shell'; plans appeal

NexImmune, Inc.

Nasdaq notified NexImmune on Nov 30, 2023 it is a 'public shell' under Listing Rule 5101.
Continued listing deemed not warranted; company subject to delisting unless timely appeal.
Company intends to request a hearing, which automatically stays delisting pending outcome.
No assurance of maintaining listing; trading in securities is highly speculative.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NexImmune, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101

Exact text from the filing

November 30, 2023, NexImmune, Inc. (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based upon Nasdaq’s review of the Company and pursuant to Nasdaq Listing Rule 5101, Nasdaq believes that the Company is a “public shell,” and that the continued listing of its securities is no longer warranted. Nasdaq’s notice also provides that, unless the Company timely appeals Nasdaq’s determination, it would be subject to delisting. Accordingly, the Company intends to timely request a hearing. The hearing reques

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-287306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.